Granulocytes
White blood cells that are characterized by granules in their cytoplasm. These include polymorphonuclear cells, eosinophils, basophils and mast cells.
Efferocytosis
The removal of effete, mainly apoptotic, cells by professional phagocytes, especially macrophages.
the exudation of proteins and influx of granulocytes from the blood. This wellcharacterized phase of the inflam matory response is routinely targeted using drugs such as nonsteroidal antiinflammatory drugs (NSAIDs) and proinflammatory cytokinenegating biologics (for example, tumour necrosis factor (TNF)specific anti bodies) that inhibit or antagonize the action of these mediators; such drugs currently form the mainstay for the treatment of chronic inflammatory disease.
Upon arrival, these leukocytes (typically polymor phonuclear cells (PMNs) in the case of non specific inflammation, or eosinophils in response to allergens) primarily function to phagocytose and eliminate tissue debris and microorganisms through distinct intracellular mechanisms (for example, involving superoxide radicals, myeloperoxidase, proteases and lactoferrins) and/or extracellular mechanisms (such as neutrophil extra cellular traps). The type of effector cells, number of cells and ability of these effector cells to neutralize the inciting stimuli probably signal the next phase of proresolution processes.
Resolution. The period between peak inflammatory cell influx and the clearance of these cells from the tissue site and the restoration of functional homeostasis -that is, classically defined resolution -is no longer consid ered a passive event during which inflammation simply fizzles out 1,2 . Instead, a complex, tightly regulated cas cade of processes occurs. First, the injurious agents that triggered the inflammatory response are eliminated. Subsequently, the synthesis of proinflammatory media tors is suspended, and any such mediators that remain are catabolized, stopping further leukocyte recruitment and oedema formation. Next, regardless of whether the initial response was PMN or eosinophildriven or adaptive to recall antigens (that is, lymphocytemediated), immune cells are cleared from the tissue. Inflammatory leukocytes can reenter systemic circulation, but many influxed PMNs, eosinophils and lymphocytes undergo local apop tosis or necrosis and subsequent efferocytosis by recruited monocytederived macrophages (MDMs). Multiple intri cate signalling mechanisms and factors control each of these processes and the balance between them, including celltocell receptor binding and humoral mediators, par ticularly bioactive lipids. Once efferocytosis is complete, macrophages can leave the inflamed site by lymphatic drainage; however, evidence also suggests that a small population may undergo local apoptosis 3 .
Post-resolution.
Recently, we demonstrated that classi cal resolution may not be the end of the local immune response; rather, there is a third phase that we termed postresolution 4 . Traditionally, resolution processes were deemed successful if acute inflammation was terminated; however, they may have a hitherto unappreci ated role in controlling adaptive immune responses and maintaining tolerance. Specifically, we found that following the reso lution of murine innate immune responses to a low dose of Saccharomyces cerevisiae cell wall extract (zymosan; administered intraperitoneally (i.p.)) or ovalbumin labelled Streptococcus pneumoniae (also i.p.), there was a previously overlooked second influx of leukocytes into tissues that persisted for weeks (FIG. 1a hi CD11c − macro phages. In addition, tissueresident (embryonic derived) macrophages -which disappeared during the acute inflammatory response -reappeared. These diverse populations of macrophages were observed alongside expansion of lymph node cell populations and increased numbers of memory T and B lymphocytes in the peripheral blood and tissue. PMNs were not observed 4 that resolution is not the end of the immune response to infection or injury, but rather that it acts as a bridge between innate and adaptive immunity, thereby adding a third phase after acute inflammation and resolution -namely, post-resolution (part a). Moreover, the idea that acute inflammation drives adaptive immunity also leads to an alternative explanation of the pathogenesis of some diseases that are driven by chronic inflammation (part b). Specifically, diseases driven by 'inflammation gone wrong' may arise from incomplete resolution of the initial acute response that, in turn, does not fully engage an appropriate adaptive immune response that would otherwise lead to full resolution. Thus, although many early-phase T helper 1-type cytokines have evolved to drive inflammation, their persistence may paradoxically derail resolution, resulting in impaired antigen clearance and the development of maladaptive immunity. IFN, interferon; IL-6, interleukin-6; PMN, polymorphonuclear cell; TNF, tumour necrosis factor. , we concluded that DCs residing in naive tissues take up antigens and migrate to local lymph nodes to stimulate the initial steps in T cell activation. As inflammation resolves, however, we found that LY6C hi MDMs and/or DCs -either from the resolving site or from peripheral blood -further amplify the adaptive arm of the response, whereas tissue resident macrophages preferentially phagocytose apop totic PMNs 4,9 . These LY6C hi MDMs remain in tissues for months after inflammation has resolved and help to dictate the magnitude and duration of subsequent acute innate inflammatory responses 4, 10 . As these observations were not seen when resolution was disrupted (FIG. 1b) , we suggest that local pro resolution processes help to bridge innate and adaptive immunity 4 (FIGS 1a,2). Thus, during resolution, a tissue microenvironment is created that facilitates interaction between the innate and adaptive arms of the immune sys tem 4 . Indeed, examples exist to support this idea: for one, inflammatory adjuvants typically aid vaccine efficacy 11 . Traditionally, adjuvants were thought to act as a depot from which the antigen was slowly released, enhancing antibody production. Now, however, they are believed primarily to trigger an acute inflammatory reaction, thereby recruiting and activating antigenpresenting cells to capture the antigen. Additionally, adjuvants are believed to possibly help to convert soluble antigens into a particulate form so that they are easily phagocytosed by antigenpresenting cells. The process of bridging innate and adaptive immunity also involves PMNs, a function elaborated in BOX 1.
Figure 2 | Acute inflammation and its resolution. Responses to infection or injury are characterized by the early and sequential release of 'go signals' -including pro-inflammatory cytokines and cell adhesion molecules -that collectively facilitate leukocyte migration into tissues. These events are counterbalanced by the concomitant release of 'stop signals', which serve to temper the severity of acute inflammation should it become too over-exuberant and cause excessive tissue injury. These signals include interleukin-10 (IL-10), prostaglandin E 2 (PGE 2 ) and factors that control the magnitude of Toll-like receptor (TLR) and nuclear factor-κB (NF-κB) signalling. Once the injurious agent is removed, pathways of resolution are activated and include removal of the inciting stimulus and destabilization of pro-inflammatory mRNAs (through expression of steroid receptor co-activator 3 (SRC3), tristetraprolin (TTP) and zinc finger CCCH domain-containing protein 12A (ZC3H12A)). The latter, along with active pro-inflammatory mediator clearance (for example, through chemokine-binding protein D6-mediated scavenging) and leukocyte death followed by efferocytosis, leads to tissue resolution. These pro-resolution events were once thought to result in inflamed tissues reverting back to homeostasis; however, it is likely that they are a prelude to the priming of adaptive immunity and also affect the imprinting of innate immunity. LRRC33, leucine-rich repeat-containing protein 33; SPM, specialized pro-resolution lipid mediator; TGFβ, transforming growth factor-β; T Reg cell, regulatory T cell. + T cellmediated clearance of the virus 12,13 . It emerges that whereas early, acute produc tion of type 1 IFNs promotes virus clearance, chronic exposure to these IFNs triggers immunosuppression through interleukin10 (IL10), programmed cell death ligand 1 (PDL1) and indolamine signalling, and causes T cell apoptosis, collectively impairing the host's ability to develop specific immunity 14, 15 . Similarly, chronic exposure to TNF attenuates T cell or adaptive immune responses. Repeated injection of TNF in mice dampens T cell responsiveness to recall antigens, whereas chronic anti TNF therapy enhances T cell reactivity 16 . Thus, whereas many early phase T helper 1 (T H 1)type cytokines drive inflammation, their persistence may paradox ically impair resolution, resulting in reduced antigen clearance and the prevention of the development of adaptive immunity or longterm immune memory (FIG. 1b) . Conceptually, many diseases driven by chronic inflammation may involve ongoing acute inflammation alongside frustrated attempts to develop adaptive immunity, with the latter ultimately turning maladaptive (FIG. 1) .
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Anti-inflammation versus pro-resolution
The idea that resolution processes cause not only the termination of inflammation but also assist the shift from innate to adaptive immunity affords additional opportunity to target diseases that involve inflammation or chronic inflammation -specifically, by promoting resolution. It has therefore been particularly important to dissociate the meaning of 'antiinflammation' from that of 'proresolution' (REFS 1,17), although it should be noted that some evidence that antiinflammatory therapy decreases macrophage populations in the synovial fluid of individuals with arthritis without inducing apoptosis suggests that the two concepts may not necessarily be mutually exclusive 18, 19 . Many investigators confuse the two concepts by reporting on the use of, for example, prophylactic (that is, preinitiating stimuli) pharmaco logical inhibition, targeted inhibition of factors expressed during early inflammatory onset, or the use of mice that overexpress or underexpress genes that are implicated in both inflammation and resolution [20] [21] [22] [23] [24] . Targeting only reso lution should involve modifying the course of an already established inflammationdriven disease, in a clinically relevant manner, by harnessing endogenous 'off switches' (be they signalling cascades or cellular interactions) that cause inflammation to resolve (FIG. 3) .
Many effective antiinflammatory treatment regimens are on the market (including NSAIDs, anti cytokine therapies and steroids); however, switching off the underlying disease processes is much more challeng ing. Hypothetically, diseases that are driven by ongoing inflammation could be treated by activating pro resolution pathways that might be pathologically silenced and/or by agonizing functional pro resolution pathways. Indeed, combining proresolution with antiinflammatory tech nology might transpire to be a superior strategy to existing approaches.
Hastening resolution was originally feared to lead to incomplete clearance of the original trigger, especially in the context of infections; however, specialized pro resolution mediators have now been shown not just to promote resolution processes, but also to augment cell ular antimicrobial function, for instance by increasing PMN and macrophage bacterial phagocytosis 25 . Thus, unlike antiinflammatory approaches, approaches to augment proresolution pathways should not increase susceptibility to infection per se.
Initiation of resolution
Generally, conventional antiinflammatory therapies are based upon the inhibition of factors that drive inflam mation -that is, they antagonize proinflammation sig nals. Although this has afforded huge success in certain fields (such as in rheumatoid arthritis and inflamma tory bowel disease) there remains scope for improve ment. Insights into resolution biology have afforded the possibility of: harnessing factors that catabolize Notwithstanding the undoubted function of polymorphonuclear cells (PMNs) in killing infection, there is a presupposition that PMNs are 'bad' in self-resolving inflammationthe context in which pro-apoptotic or pro-efferocytosis drugs have been tested. Previously, we made a link between the classic model of acute inflammatory resolution and the establishment of adaptive immunity. Others have also made important observations that indicate a hitherto unappreciated role for PMNs in this process, including that of 'lymph-node cell shut-down'.
The term lymph-node cell shut-down describes how -unlike in the steady state, when the rate of lymph flow and the output of cells in the efferent lymph is constantthere is a transitory decrease of lymphocytes exiting the efferent lymph within hours of antigen or adjuvant injection [154] [155] [156] . Lymph-node cell shut-down is thought to facilitate the development of adaptive immunity. Lipid mediators including prostaglandin E 2 (PGE 2 ) and thromboxane A 2 are thought to be the crucial components in this process 155, 157 . A later study showed that, within minutes of infection or vaccination, PMNs from the inflamed tissue transit to regional draining lymph nodes and suppress ensuing CD4 + and B cell responses in a thromboxane-mediated process 158 . Although it is believed that PMN prostanoids directly inhibit T cell and B cell responses by inhibiting their proliferation, recent studies suggest that PGE 2 may, for instance, drive responses of CD4 + T helper 1 immune cells 159 . In addition, PMNs compete with dendritic cells (DCs) for antigens, limiting antigen availability to DCs; such competition may further compromise the quality of adaptive immune responses.
Thus, although we appreciate the established role PMNs have as first-line defenders against pathogens, these cells also play an important part in modulating adaptive immune responses. Whether these effects are beneficial to the host depends on the nature of the inflammatory stimulus -infection or vaccination. However, what is clear is the need to understand the broader role PMNs have during acute inflammation, and the effect that hastening PMN apoptosis may have on the nature and magnitude of the ensuing adaptive immune response. Moreover, the role of PMNs in modulating T cell or B cell responses in chronic inflammation that is driven by maladaptive immunity warrants further investigation. It is for this reason that we need to develop more-reflective models of chronic inflammation in order to establish the overall virtues and limitations associated with hastening PMN apoptosis; the role of granulocytes in chronic, maladaptive immunity may not be the same as in acute inflammation.
Adenine-or uridine-rich elements (AREs). 3ʹ-untranslated regions of mRNA that recruit destabilizing factors and translational silencers. proinflammatory signalling; inhibiting pathways that break down pro resolution mediators; or selectively and potently activating receptors on which proresolution mediators act. The processes described below that lead to resolution and the factors that control these processes are not tied to any disease or tissue but recount, in general terms, advances made in resolution biology.
Removal of stimuli. For resolution to occur effectively, the initiating injurious agents must be eliminated. This is particularly relevant for autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus (SLE) that are driven by intractable endogenous anti gens 26, 27 . In the case of bacterial infection, the removal of the pathogen is facilitated in part by NADPH oxidase mediated killing by PMNs 28 . Defects in the assembly of NADPH subunits, as occurs in the immunodeficiency disorder chronic granulomatous disease, demonstrate the importance of antigen clearance for resolution 29 .
Dampening pro-inflammatory signalling. Following stimulus removal, it is rational to suggest that the var ious families of receptors and their signalling pathways that triggered the release of proinflammatory mediators must be turned off in order to prevent collateral dam age from an ongoing proinflammatory state. Sepsis is a good example of when this does not occur: a cytokine storm may be witnessed despite negative bacterial blood cultures, suggesting exaggerated and persistent activa tion of the innate immune system despite removal of the inciting stimulus. A number of regulatory mechanisms have evolved to keep the signalling factors that drive the innate immune system in check 30 . For example, the transmembrane molecule leucine rich repeatcontaining protein 33 (LRRC33) negatively regulates Tolllike receptor (TLR) signalling and subse quent nuclear factorκB (NFκB) activation, thus damp ening TLRdriven proinflammatory events 31 . LRRC33 is functionally similar to RP105 (also known as CD180), an endogenous inhibitor of TLR4 signalling. DCs lack ing RP105 exhibit increased NFκB activation and pro inflammatory signalling in response to lipopoly saccharide (LPS) challenge 32 . Separately, the multifunctional de ubiquitinase cylindromatosis was recently shown to negatively regulate NFκB signalling and to be an induc ible negativefeedback regulator of bacteria induced inflammation 33 . Additionally, the immune suppressive lipid mediator prosta glandin E 2 (PGE 2 ) 34 inhibits protein expression of TLR4 (REF. 35 ). Taken together, mediators such as LRRC33, RP105, cylindromatosis and PGE 2 typ ically ensure that inflammatory signalling is dampened after acute inflammatory responses.
Posttranscriptional regulatory mechanisms -such as those that restrict the stability and/or translation of various mRNAs -have also evolved. Many of these mRNAs possess adenine-or uridine-rich elements (AREs) that recruit destabilizing factors and translational silenc ers to their 3ʹuntranslated regions (UTRs) 36 . ARE binding proteins that destabilize these mRNAs include tristetraprolin (TTP), Brelated factor 1 (BRF1), BRF2, KHtype splicing regulatory protein (KSRP; also known as FUBP2) and ARE RNAbinding protein 1 (AUF1). TTP interacts with AREs through its zinc finger and destabilizes mRNA transcripts that encode several inflammatory modulators, including granulocytemacrophage colonystimulating factor (GMCSF) 37 , CSF 25 , IL2 (REF. 38 ), IL6 (REF. 39 ), inducible nitric oxide synthase (iNOS) 40 , cyclooxygenase 2 (COX2) 41 , IFNγ 42 and TNF 43 . Transcription of TTP itself is also triggered in a feedback loop by inflammatorylike stimuli including TNF 43 , LPS 44 , and IFNγ 39 in order to dampen the expres sion of inflammatory cytokines and promote resolution of inflammation 43 . By contrast, AREbinding proteins that inhibit mRNA translation include T cell intracell ular antigen 1 (TIA1), TIA1related protein (TIAR), CUG triplet repeat RNAbinding protein 2 (CUGBP2; also known as CELF2) and fragile Xrelated protein 1 (FXR1) 45, 46 . Targeted deletion of the gene encoding TIAR It is important to emphasize the difference between anti-inflammation (part a) and pro-resolution (part b). The former describes the inhibition of factors that drive inflammation, including vasoactive amines, eicosanoids, cytokines, chemokines and cell adhesion molecules. Among the pharmacological tools developed to achieve this clinically are non-steroidal anti-inflammatory drugs and biologicals such as anti-tumour necrosis factor (TNF) therapies. This form of intervention dampens inflammation from the onset, with or without accelerated resolution. By comparison, pro-resolution describes enhancing or promoting the factors essential for removal of the inciting stimulus as well as dampening pro-inflammatory signalling, followed by leukocyte clearance. It is envisioned that pro-resolution therapies will not necessarily affect onset but will accelerate resolution. enhances the production of proinflammatory proteins in LPSactivated macrophages, and mice lacking TIA1 are more susceptible to LPSinduced septic shock than wildtype littermates, owing to an overproduction of TNF 47 . The factors described here that regulate pro inflammatory signalling at the mRNA level therefore represent alternative targets for the development of novel drugs to treat diseases driven by ongoing or over exuberant inflammation.
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Steroid receptor coactivator 3 (SRC3; also known as NCOA3) is a component of transcription factor com plexes that involve NFκB, peroxisome proliferator activated receptors (PPARs) or the glucocorticoid receptor. Interestingly, SRC3 can either promote or inhibit inflam matory responses by regulating rates of mRNA transcrip tion. Ncoa3 −/− mice are hypersensitive to LPS challenge because they overexpress proinflammatory cytokines such as TNF, IL6 and IL1β. Specifically, the translation of Tnf and Il1b transcripts is higher in the macro phages of these SRC3lacking mice than in the macrophages of wild type controls. In wildtype mouse macrophages, SRC3 binds to TIA1, leading to an increase in the binding of TIA1 to the ARE of Tnf mRNA, inhibiting its translation. Thus, SRC3 and TIA1 cooperatively repress the expres sion of reporter constructs that bear the TNF 3ʹUTR. Together, these findings show that SRC3 functions as both a transcriptional coactivator and a translational co repressor. This is an example of a regulatory protein that is involved in both the initiation and resolution phases of the inflammatory response, thereby representing a pos sible opportunity to increase or reduce inflammation as clinically appropriate.
IFNγtreated macrophages provide another exam ple of a mechanism of temporally staggered negative feedback inhibition of cell activation 48 . IFNγ induces the expression of the acutephase response protein ceruloplasmin 48, 49 as well as the assembly of the IFNγ activated inhibitor of translation (GAIT) complex, which binds to the GAIT element. The GAIT element is a 29nucleotide hairpin found in the 3ʹUTRs of cerulo plasmin mRNA, which, in turn, targets components of the translation initiation machinery to inhibit protein synthesis 50 . As a result, after ceruloplasmin is secreted from IFNγactivated macrophages to combat infection or injury, its synthesis is turned off. Transcripts encod ing several other inflammatory mediators -including CCchemokine ligand 22 (CCL22), CCchemokine receptor 3 (CCR3), CCR4 and CCR6 -contain func tional GAIT elements 51, 52 , suggesting that the GAIT complex has an important influence on the magnitude and duration of inflammatory reactions.
The transcription factor zinc finger CCCH domain containing protein 12A (ZC3H12A) acts downstream of CCL2 and is another immunoregulatory zincfinger protein that negatively regulates macro phage activation and TNF and iNOS production; it does this by inhib iting NFκB 53 . Indeed, production of IL6 and IL12β (also known as IL12 subunit p40), but not of TNF, is increased in TLRactivated ZC3H12Adeficient mouse macrophages owing to increased Il6 and Il12b mRNA stability. In addition, ZC3H12Adeficient mice succumb to a chronic inflammatory condition that is characterized by increased levels of immunoglobulins and autoanti bodies, increased lunginfiltrated leukocytes and hyper responsive T cells and macrophages 54 . Several microRNAs (mi RNAs) have emerged as key regulators of TLR proinflammatory signalling path ways. For example, the NFκBinducible miRNA miR146 inhibits translation of mRNA encoding IL1 receptor associated kinase 1 (IRAK1), IRAK2 and TNF receptorassociated factor 6 (TRAF6) 55 . As IRAK1 and TRAF6 are required for NFκB activation, this func tion of miR146 leads to a negative regulatory loop 56 . By corollary, overexpression of miR146 results in a decrease in levels of various chemokines and cytokines, including CCL5 (REF. 56 ), IL6, CXC chemokine ligand 8 (CXCL8) 57, 58 and IL1β 59 , and thereby prevents over inflammation, bringing the system back to homeo stasis. As expected, mir-146aknockout mice exhibit loss of immunological tolerance, and their macrophages are hyperresponsive to LPS. Another miRNA, miR21, is induced in macrophages by NFκB and MYD88 upon LPS stimulation. miR21 controls inflammation by downregulating the translation of the proinflammatory tumour suppressor programmed cell death 4 (PD4) 60 , an inhibitor of IL10 production. As IL10 blocks NFκB, miR21 represents another negative feedback regulator of LPSdriven inflammation with potential in the resolution of inflammation.
Elucidating the role of negative feedback regulators of inflammation is an attractive strategy. Indeed, mi RNAs are increasingly popular drug targets. Proteins that are considered difficult to modulate pharmacologically can now be targeted through their miRNA gene regulators, enabling the treatment of currently seemingly untract able diseases. Targeting mi RNAs requires innovation at the level of drug discovery; this is well described elsewhere (see REF. 61 ).
However, not all mi RNAs or AREbinding proteins dampen proinflammatory signalling pathways. For example, miR155 (REFS 62, 63) enhances the expres sion of TNF in macrophages, and zinc finger CCHC domaincontaining protein 11 (ZCCHC11) stabilizes mRNA that encodes IL6 (REF. 64 ). Nonetheless, defects in one or more AREbinding proteins and/or mi RNAs could explain the aetiology of some ongoing inflam mationdriven diseases, such as sepsis. Although there is more study of antiinflammatory signalling pathways (such as cyclic AMP, IL10 and transforming growth factorβ1 (TGFβ1)) than of the negative regulation of proinflammatory signalling pathways, the latter nonetheless represents a critically important aspect of biology and medicine. Moreover, this area of research provides an opportunity to pharmacologically manipu late their function to switch off persistent inflammation at its source.
Clearance of pro-inflammatory mediators. Following disposal of the injurious agent and turning off signalling pathways, the levels of cytokines, chemokines, eicosa noids, cell adhesion molecules and other inflammatory mediators must revert back to their preinflamed state. 
Resolution
Cell death and the clearance of effete leukocytes is an area of resolution biology that has been studied in much detail and, as a consequence, has the potential to provide numerous targets for proresolution drug development. Here, we discuss the many fates of cells during resolu tion, with a focus on the local death of PMNs and their efferocytosis by mononuclear cells.
Leukocyte death. Inflammatory cells can be eliminated in one of three ways: through retrotransendothelial migration back into systemic circulation; through lymphatic drainage (to enable subsequent participa tion in adaptive immune responses); or through cell death in the inflamed tissue. Local cell death occurs in many ways, including through autophagy, excitotoxicity, pyroptosis, necrosis, necroptosis, neutrophil extracellu lar trap (NET)osis and caspasemediated apoptosis 69, 70 (BOX 2). The predominant mechanism of cell death in a given disease state is not without reason or conse quence; instead, it plays an active part in determining the outcome of inflammation.
Granulocyte death by apoptosis during resolution has been extensively studied (see below). Key molecules and pathways involved in maintenance of leukocyte survival or apoptotic death include NFκB, phosphoinositide Autophagy is the ordered degradation and recycling of unnecessary or dysfunctional intracellular components. Autophagic cell death occurs after nutrient deprivation or growth factor withdrawal, or in response to rapamycin or inflammatory-like stimuli such as Toll-like receptor (TLR) agonists, phorbol myristate acetate (PMA) or reactive oxygen species. It typically occurs without chromatin condensation and is accompanied by cytoplasm vacuolization 160 . Autophagy provides a mechanism for the elimination of intracellular microorganisms. It also controls inflammation -via regulatory interactions with innate immune signalling pathways -by removing endogenous inflammasome agonists and through various effects on the secretion of different immune mediators 161 . In addition to autophagy, polymorphonuclear cell (PMN) extracellular traps, or NETs, that are composed of DNA and granule constituents lead to a form of non-apoptotic cell death termed NETosis 162 . Although NETs are designed to kill bacteria and fungi, they are proposed to worsen inflammation. Consistent with this, PMNs isolated from the synovial fluid or peripheral blood of patients with acute gout -an inflammatory condition associated with the accumulation of uric acid in synovial joints -produce NETs 163 . Cells may also undergo necrosis in response to signalling through tumour necrosis factor (TNF) family death receptors, pathogen sensors, antigen-specific T cell receptors and genotoxic stress. Necrosis can occur either as a primary event (in which case, it is known as primary necrosis), or secondary to apoptosis, if apoptotic bodies are not immediately cleared (as in the presence of pathogen-encoded caspase inhibitors) 164 . Necrosis was traditionally viewed as an uncontrolled mode of cell death until it was found that certain types of necrosis are tightly regulated by signal transduction pathways. In particular, the receptor-interacting serine/threonine protein kinase 1 (RIPK1) family member RIPK3 is now considered a key mediator in caspaseindependent cell death 164, 165 , which is now known as necroptosis or programmed necrosis. Some pathogens in monocyte-macrophages, PMNs and eosinophils can disrupt death pathways as a survival strategy, impairing the antimicrobial functions of immune cells 166, 167 . Although necrosis has been traditionally associated with enhanced inflammation and tissue injury and therefore considered to be 'unwanted' (REF. 168 ), it has been suggested that necrotic cell death can inhibit inflammatory reactions 169 . For example, annexin A1, a glucocorticoid-inducible anti-inflammatory and pro-efferocytotic protein, is externalized on granulocytes during secondary necrosis. Here, it acts as an immune-dampening system, counteracting inflammatory responses when apoptotic cells are not cleared 170 . The relative virtues of the effects of necrotic cell death in inflammation are beyond the scope of this Review, but these findings muddy the waters in terms of what was once thought to be good cell death (apoptosis) versus bad death (necrosis). Indeed, whereas autophagic-like PMNs have been reported in rheumatoid arthritis, septic shock and cystic fibrosis 171, 172 , a recent study in gout proposed that aggregated NETs promote the resolution of PMN-driven inflammation by degrading cytokines and chemokines and disrupting PMN recruitment and activation 173 . Thus, as the mode of cell death during resolution may be dependent on tissue-environmental cues, it may also be tissue-and disease-specific.
Non-phlogistic
In a non-inflammatory manner.
3kinase (PI3K), myeloid leukaemia cell differentiation protein 1 (MCL1) and cAMP. Regulated clearance of apoptotic cells leads to a shutdown of immune cel lular activity (in particular, that of efferocyto sing macrophages) and the consequent inhibition of inflam matory responses. Therefore, it is considered that granulocyte apoptosis followed by phagocytosis (effero cytosis) is the most 'desirable' form of cell death for successful resolution 71 . Granulocytes survive in the circulation for only a few hours, but various soluble mediators released at sites of inflammation can influence the survival of diverse granulocyte subtypes. For example, PMN longev ity is extended by IL6, IL8, GMCSF and bacterial products, whereas eosinophil survival is augmented by cytokines such as IL3, IL5 and GMCSF 72 . In turn, these survival factors activate several signalling pathways, including the cyclindependentkinase (CDK), NFκB, PI3K-AKT, cAMP and mitogenactivated protein kinase (MAPK) pathways 73 . Generally, these signalling path ways lead to enhanced levels of pro survival molecules and diminished levels of proapoptotic molecules. NFκB, in particular, alters the expression of many intracellular prosurvival proteins, including B cell lymphoma 2 (BCL2) family members (such as BCLX L and Xlinked inhibitor of apoptosis protein (XIAP)). Therefore, pharmacological inhibition of NFκB and inhibitor of NFκB kinaseα (IKKα) influences granulo cyte survival and apoptosis and consequently drives inflammatory resolution 74 . In addition to NFκB, the intracellular proapoptotic protein BCL2associated agonist of cell death (BAD) is an important downstream target of PI3K-AKT. AKT phosphorylates BAD, thereby suppressing apoptosis and promoting cell survival 75 . In myelin oligodendro cyte glycoproteininduced experimental autoimmune encephalomyelitis (a model of multiple sclerosis), PI3Kγdeficient mice developed milder clinical disease and had decreased levels of CCL2 and CCL5 in brain tissue compared with wildtype controls, and showed increased leukocyte apoptosis 76 . Importantly, neither PI3Kγ deficiency nor the PI3K inhibitor AS605240 affected the magnitude of the acute onset phase of the disease, indicating that in this model, PI3Kγ may have a role in promoting leukocyte survival -preventing resolution and extending inflammation.
The role of cAMP in apoptosis is complex: in some cells types it drives programmed cell death, whereas in others it prevents it 77 . For instance, in vitro cAMP inhibits granulocyte apoptosis and the subsequent recognition and uptake of apoptotic granulocytes by macrophages 78, 79 . However, increasing cAMP func tion (with the phosphodiesterase 4 inhibitor rolipram, the adenylyl cyclase activator forskolin or the cAMP analogue dbcAMP) in LPSinduced pleurisy 4 hours after LPS challenge dosedependently prevented PMN accumulation but, in contrast to in vitro studies, pro moted PMN apoptosis 80 . Independent of its effects on phagocytosis of apoptotic cells, rolipram causes a direct, cAMPdependent switch of M1like proinflammatory macrophages to resemble those found during resolving inflammation 81 . Collectively, these findings show that cAMP signalling regulates processes that limit tissue injury, and that modulation of cAMP levels possibly represents a central therapeutic strategy in the con trol of resolution. However, this will most probably be dependent on context, tissue and stage of inflammation.
All MAPK subtypes (namely, extracellularsignal regulated kinase 1 (ERK1) and ERK2, JUN Nterminal kinases (JNKs) and p38 MAPK) play a part in modulating granulocyte apoptosis. However, their respective roles in cell survival are celltype and contextspecific 82 . ERK is typically associated with the regulation of activation and survival of various cell types, including granulo cytes 83 . In carrageenaninduced pleurisy, for instance, the ERK1 and ERK2 inhibitor PD98059 hastens resolution of inflammation, with fewer PMNs and macrophages in the pleural cavity and increased PMN apoptosis 84 . By contrast, the exact role of p38 MAPK in the control of granulocyte survival is controversial; this pathway has been described to have both proapoptotic 85 and anti apoptotic 86 effects. During resolution, the restriction of p38 MAPK activation by MAPK phosphatase 1 controls the proinflammatory to antiinflammatory switch of macro phage polarization during muscle healing 87 . Further, during the non-phlogistic phagocytosis of apoptotic cells, the p38 MAPK signalling pathway leads to the activa tion of certain transcription factors that reprogramme the macro phage phenotype from proinflammatory to antiinflammatory, resulting in release of IL10 (REF. 88 ).
A role for CDK in granulocyte survival and in delay ing resolution in experimental animal models was illustrated using the CDK inhibitor roscovitine, which inhibits the ability of CDK7 and CDK9 to phosphoryl ate RNA polymerase II 89 . This compound caused apop tosis of GMCSF, LPS or glucocorticoidstimulated human PMNs 90, 91 . Additionally, roscovitine and AT7519 (a CDK inhibitor in clinical trials for the treatment of cancers, neurodegenerative diseases, viral infections and glomeru lonephritis) dosedependently induced apoptosis of human eosinophils 92 . Importantly, in vivo, roscovitine enhanced the resolution of established PMNdependent inflammation in models such as carrageenaninduced pleurisy, carrageenaninduced arthritis and bleomycininduced lung injury 90 . More over, in a murine model of ovalbumininduced allergic pleurisy, AT7519 triggered eosinophil apoptosis and subsequent phagocytic clearance 92 . These data highlight the importance of phagocytic clearance of inflammatory cells to the resolution process.
Overall, targeting death pathways of pathogenic cells that persist at sites of chronic inflammation has its virtues. The effectiveness of this approach will depend on being able to selectively target cells of interestsuch as PMNs, eosinophils or T H 1type lymphocytes -and at the right site, while leaving proresolving, prohomeostatic and bystander cells intact.
Clearance of dead cells. Defective clearance of apoptotic bodies has been linked with autoimmunity 93 and other chronic inflammatory diseases 94 ; as a result, effero cytosis has been considered a key requirement for inflammatory
Co-inhibitory molecules
Molecules belonging to the immunoglobulin superfamily or the tumour necrosis factor receptor superfamily that inhibit T cell receptormediated responses.
Polysensitization
A phenomenon in which sensitization to one allergen favours sensitization to other environmental allergens.
Macrophage plasticity
The ability of macrophages to alter or adapt their biological function commensurate with the inflammatory environment they inhabit.
resolution and for the preservation of immune tolerance 71 . When a PMN nears the end of its life, it releases chemo attractants such as nucleotides 95 , lyso phosphatidyl choline 96 105 . The interaction between tissue resident macrophages and these eatme sig nals [105] [106] [107] [108] [109] ensures that apoptotic cells are efficiently removed from the tissue before membrane rupture and the release of histo toxic mediators that would perpetuate the inflammatory response.
Importantly, uptake of apoptotic cells triggers the conversion of phagocytosing macrophages to an immuneregulatory or proresolution phenotype 81, 110 , maintaining immune tolerance both locally and in draining lymphoid organs and limiting potential collat eral tissue damage 4, [111] [112] [113] . This phenotype is character ized by upregulated expression of co-inhibitory molecules such as PDL1 and ICOS ligand; the release of the anti inflammatory cytokines IL10 and TGFβ; the secretion of PCNAassociated factor, PGE 2 and cAMP 81, [114] [115] [116] ; and the inhibition of the release of proinflammatory cytokines including TNF, GMCSF, IL1β, IL12 and IL18 (REFS 25, (59) (60) (61) . Macrophages that have ingested apoptotic cells also release proresolving lipid medi ators such as RvE1, protectin D1 and maresins 101, 117 , contributing to termination of the inflammatory process.
There are hypothetical benefits in therapeutically triggering apoptosis to accelerate resolution, but this must be accompanied by robust efferocytosis, as apop totic cells and their associated autoantigens potentially underlie disease progression in SLE 93 . Moreover, as dis cussed below, efferocytosis is an immunosuppressive process and so opens a window of potential infectious opportunity 118 . Therefore, a better understanding of the interaction between apoptotic cells and phagocytosis, and of the soluble mediators that modulate this process, will be important in both understanding the pathogen esis of chronic diseases and delineating novel ways of treating them.
Macrophage phenotypes during resolution
Early studies on acute inflammation suggested that PMN clearance and the restoration of tissue homeostasis represented the end of successful resolution 2, 17 . However, as described above, we recently reported on a third phase of inflammation, which we called postresolution, in a murine model of zymosaninduced peritonitis, sug gesting that the classic view of resolution needed to be expanded 4 . This phase persisted for weeks and involved popula tions of LY6C hi MDSCs, DCs and macrophages. These monocytederived cells amplified the ensuing adaptive immune response and maintained immune tolerance by generating inducible regulatory T cells 4 . We 4 and others 10 also found that LY6C hi MDMs remained in tis sues for months after inflammation had resolved, and that these cells had a role in dictating the magnitude and duration of subsequent acute innate inflammatory stimulation (reminiscent of studies of polysensitization). In another study in mice, DCs were found not to return to their steadystate phenotype after resolution of T H 2mediated inflammation; instead, they persistently expressed high levels of costimulatory molecules such as CD80, CD86 and intercellular adhesion molecule 1, and the T H 2skewing molecules OX40 ligand and lec tins YM1 and YM2. This sustained maturation status of airway DCs facilitated neosensitization for up to at least 1 month after resolution 119 . These findings emphasize that, once inflammation has resolved, there is a hitherto unappreciated phase of 'adapted homeostasis' , in which cells of the monocyte-macrophage lineage play a central part in modulating subsequent responses to infection or allergens.
Therefore, despite experiencing the same inflamma tory cues, monocyte or macrophage populations might come to possess diverse phenotypes that are neither M1 (proinflammatory) nor M2 (antiinflammatory), but commensurate with the phase of inflammation. Indeed, this notion probably extends to macrophage popula tions in tissue niches under different physiological and disease conditions 120, 121 . For instance, during the max imal fibrotic stage of liver fibrosis elicited by carbon tetrachloride, LY6C hi monocytes give rise to MDMs 122 . These macrophages are a hybrid of the conventional M1 and M2like cell phenotypes, express elevated levels of growth factors and tissue remodellingrelated factors needed to clear fibrotic plaques, and exhibit elevated ERK signalling. Interestingly, using liposomes to ele vate ERK signalling enhanced antifibrotic macrophage phagocytosis in vivo, and pharmacologically elevating the phagocytic nature of antifibrotic macrophages using liposomes accelerated the resolution of liver fibrosis.
Data from these reports support the idea of macrophage plasticity -that the macrophage phenotypes that either drive or resolve diseases will be tissue, stim ulus and phasespecific. Indeed, diverse populations of macrophage phenotypes have been reported in various experimental models of renal (that is, singleorgan) inflammation (for a review see REF. 123 ). The precise nature of macrophage phenotypes involved in each disease will depend on which disease mechanism pre dominates in a given organ. Whereas infection and cell necrosis trigger the generation of proinflammatory or M1like macrophages that exacerbate renal cell dam age, apoptotic cells induce antiinflammatory, immune suppressive macrophages that promote epithelial and
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Sites where untranslated mRNAs accumulate in cells that have been subjected to adverse environmental conditions. vascular repair. Indeed, vascular and epithelial healing that is insufficient despite abundant growth factor secre tion will promote profibrotic 'M2a' or 'woundhealing' macrophages that accelerate fibrogenesis. In a separate example, inflammatory monocytes recruited to sites of skeletal muscle injury switched into antiinflammatory macrophages to support myogenesis 124 in a manner dependent on AMPKα1 (5ʹAMPactivated protein kinase catalytic subunit α1) 125 , a master regulator of energy homeostasis. Thus, similar to the peritoneum 4 , a single organ such as the kidney (or tissue such as skel etal muscle) can generate diverse populations of immune cells depending on disease aetiology.
These data indicate that there are many diverse routes to resolution; thus, it is unlikely that one single therapeutic intervention will be a panacea for all chronic inflammatory diseases. Instead, it will be increasingly imperative to focus on a specific pathology, appreciating both the hetero geneity within classical clinical diagnoses and the factors that influence the inflammatory phenotype, to successfully administer targeted proresolution therapy.
Targeting pro-resolution pathways
The aspects of the proresolution cascade described above can be targeted to alter the inflammatory profile, with out compromising immune tolerance. Modulating any of these events -along with supplementation of, or inhibi tion of the catabolism of, soluble proresolution factors to extend their pharmacological halflife -represents a tractable strategy to invoke resolution. TABLE 1 describes most of the currently known mediators, receptors and mechanisms that exert proresolution actions.
The number, intricacy and applications of human inflammatory models are increasing (BOX 3), but zebra fish and mice (BOX 4) have provided us with the quanti fiable resolution indices we use in these models. These indices include the maximum cell number present at the peak of the inflammatory response (Ψ max ), the time at which Ψ max occurs (T max ), and the time at which cell numbers are reduced by 50% of Ψ MAX (T 50 ). The reso lution interval (R i ) is the time taken for cells at Ψ max to reach T 50 (that is, to be reduced by 50%) 126 . These metrics allow comparative study of the efficacy of existing and novel proresolution therapies.
In terms of modulating cell recruitment to sites of infection or injury, and as mentioned above, it is impor tant to differentiate between (antiinflammatory) fac tors that only inhibit granulocyte trafficking into tissues (such as metformin 127 ) versus those that that are also proresolution. For instance, lipoxins and resolvins inhibit PMN trafficking and enhance efferocytosis of apoptotic cells without compromising host defence 128 , and RvD1, RvD5 and protectin D1 accelerate leukocytemediated killing of bacteria and enhance antibiotic efficacy 25 . There are several strategies for enhancing PMN apop tosis in vivo -including CDK inhibition (using rosco vitine or AT7519) or inhibition of PI3K, ERK1, ERK2 or NFκB (using the PGD 2 metabolite 15deoxyΔ 12-14 PGJ 2 ) 129 . However, for maximum benefit, this must be accompanied by efferocytosis by macrophages. This can be augmented by melanocortins, glucocorticoids, annexin A1 and its mimetic Ac226, as well as lipid mediators 130 . Recently, Bcl2overexpressing mice showed impaired PMN apoptosis in a model of pneumococcal meningitis, and this effect was accompanied by high levels of IL1β and granulocyteCSF, and reduced levels of antiinflammatory TGFβ, resulting in persistence and prolonged activity of PMNs and thus moresevere disease 131 . Inducing PMN apoptosis using the CDK inhibitor roscovitine reduced the associated brain parenchymal tissue and accelerated recovery following pneumococcal meningitis.
Although hastened PMN apoptosis and the result ant reprogramming of macrophages towards an immunemodulatory or proresolution phenotype may be beneficial, resolving inflammation before the tissue is fully immunologically restored may open a window of 'infectious opportunity' . The lung, for instance, is highly susceptible to secondary bacterial infections as a conse quence of injury. Apoptotic cells suppress in vitro phago cytosis and killing of bacteria by alveolar macrophages in a PGE 2 , PGE 2 receptor EP2 subtype (PTGER2) and cAMPmediated manner 118 . Intrapulmonary administra tion of apoptotic thymocytes impaired lung recruitment of PMNs as well as clearance of Streptococcus pneumoniae, again through a PGE 2 and PTGER2dependent pathway. These results suggest that, in addition to their beneficial homeostatic influence, proresolution programmes, at least in the lung, may dampen innate antimicrobial responses, leaving the host susceptible to secondary infection and perhaps necessitating the concomitant use of immunerestorative agents such as PTGER2 antagonists to counteract these effects 34 . Moreover, the contrast between these findings from dif ferent infected sites (meninges and lung) reemphasizes that the effects of various proresolution pathways on tissue integrity, repair and susceptibility to infection are most probably disease and tissuespecific.
Lipid mediators such as PGJ 2 and RvD1 exert multi ple levels of control on the inflammatory response, and mimetics based on their mode of action through G proteincoupled receptors (GPCRs) represent a tract able and very effective target for treating on going inflammation 132 . PGJ 2 was one of the first COXderived lipid mediators implicated as eliciting the resolu tion of innateimmune inflammatory responses 133 as well as regulating adaptiveimmune inflammatory responses [134] [135] [136] . PGJ 2 is an agonist of the GPCR PPARγ; it represses the transcription of mRNAs encoding proinflammatory mediators, inhibits protein trans lation 137 and inhibits NFκBmediated transcription of proinflammatory genes 138 . PGJ 2 mediated transla tional repression triggers a stress response, resulting in the assembly of stress granules 139, 140 that reprogramme gene expression to allow cells to survive noxious stim uli. Complementarily, RvD1 upregu lates miR146 to control NFκB expression 141 . RvD1 also upregulates miR219 and miR208a (the latter of which triggers IL10 expression) in exudate cells isolated from the GPCR Nformyl peptide receptor 2 (FPR2; also known as ALX)overexpressing transgenic mice bearing a zymosan induced peritonitis. In Fpr2knockout mice, RvD1 had no effect on leukocyte infiltration, did not regulate miR208a 
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αMSH, α-melanocyte-stimulating hormone; Ac2-26, annexin A1 N-terminal derived peptide; BLT1, leukotriene B 4 receptor 1; cAMP, cyclic AMP; CDK, cyclin-dependent kinase; CMKLR1, chemokine-like receptor 1 (also known as ChemR23); CO, carbon monoxide; D6, chemokine-binding protein; ERK, extracellular-signal-regulated kinase; FPR, N-formyl peptide receptor; GPR, G-protein coupled receptor; H 2 S, hydrogen sulfide; LRRC33, leucine-rich repeat-containing protein 33; MC3R, melanocortin receptor 3; ND, none defined; NF-κB, nuclear factor-κB; PGD 2 , prostaglandin D 2 ; PGJ 2 , prostaglandin J 2 ; PI3K, phosphoinositide 3-kinase; PPARγ, peroxisome proliferator-activated receptor-γ; TTP, tristetraprolin. *D6 acts as a scavenger decoy receptor.
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and had no subsequent effect on IL10 expression 142 , suggesting that the actions of RvD1 are dependent on FPR2. Targeted, stratified application of either of these agents, either locally or systemically, could therefore potentially help to drive resolution in inflamed tissues.
It must be emphasized that the targets discussed above are involved in pathways pertinent to acute, selfresolving inflammation. Whereas it is relatively easy to make alreadyresolving experimental inflam mation resolve even faster, it is far more challenging, though more clinically relevant, to achieve this in dis eases of different aetiology, chronicity and complexity. Granulomatous experimental autoimmune thyroiditis (GEAT) is a T cellmediated autoimmune disease that can be induced in genetically susceptible strains of mice by immunization with mouse thyroglobulin and adju vant 143 . It is characterized by proliferation of thyroid epithelial cells, granuloma formation and infiltration of T lymphocytes, macrophages, multinucleated giant cells and PMNs. Neutralizing the endogenous pro apoptotic molecule TNFrelated apoptosisinducing ligand (TRAIL) in this model has little effect on the development of the lesion, but markedly inhibits lesion resolution 144, 145 . In mice that received a TRAILspecific antibody, the inhibition of resolution correlated with the expression of TRAIL and of the antiapoptotic mol ecules FLICElike inhibitory protein (FLIP) and BCLX L on thyroid inflammatory cells. These results suggest that endogenous TRAIL is not required for GEAT initiation and development but is crucial for GEAT resolution. Furthermore, TRAIL accelerated PMN apoptosis and resolution in LPSmediated acute lung injury and in zymosaninduced peritonitis 146 . Therefore, TRAIL may promote resolution of chronic inflammatory disease processes, at least in part through altering the expres sion pattern of pro and antiapoptotic molecules of both tissue stromal and inflammatory cells. The exam ple of TRAIL emphasizes that the resolution of complex chronic diseases (as well as of acute inflammation) is therapeutically achievable.
Whereas the targets discussed here and elsewhere were empirically found to promote resolution, there are other drugs that exert striking antiinflammatory as well as proresolution effects. Specifically, hydrogen sulfide (H 2 S) has the antiinflammatory effects of inhibiting granulocyte adhesion to, and transmigration across, the microvascular endothelium and inhibiting myelo peroxidase activity; moreover, it also helps to resolve inflammation by promoting the apoptosis of PMNs, the uptake of bacteria by phagocytes and the acquisition of an M2like phenotype by macrophages 147 , as well as by promoting tissue repair and restoration of tissue func tion 148 . Some of the proresolution properties of H 2 S arise from its ability to selectively induce the expression and activity of inducible COX, which produces pro resolution lipid mediators. Inhibition of H 2 S synthesis in the gut leads to reduced COX expression, an increase in mucosal inflammation and impaired healing of experi mentally damaged tissue -effects that may be rescued by H 2 S donors. As a consequence, several groups began to try to develop novel therapeutics that release H 2 S 149 . ATB429 from Antibe Therapeutics is a derivative of the antiinflammatory drug mesalamine that releases H 2 S. ATB429 exhibits markedly enhanced antiinflammatory, proresolution and prohealing effects in rodent models of colitis compared with mesalamine, and the
Box 3 | Challenges with translation into humans
Animal models of inflammation and resolution (BOX 4) have generated invaluable information on cell trafficking and cell clearance, as well as the receptors and soluble mediators that control these processes; however, their relevance to human physiology and pathology has been questioned. The disparity between rodent and human experimental medicine was exemplified by a recent report showing that although acute inflammatory stimuli such as trauma, burns and endotoxin result in highly stereotyped genomic responses in humans, the equivalent responses in mouse models were not comparable 174 . Although controversial 175, 176 , Seok et al. 174 called for "higher priority for translational medical research to focus on the more complex human conditions rather than relying on mouse models to study human inflammatory diseases". This is not without difficulty. Studying fundamental resolution biology in the clinical population is challenging, being complicated by demographic variables, polypharmacy, sample timing with regard to disease stage, and other factors. Further, there are inevitably complex interactions between concomitant pathologies and resolution pathways, as exemplified in atherosclerosis and hyperglycaemia.
Atherosclerosis is initiated by shear stress and the deposition of cholesterol-rich lipoproteins in the artery wall, and results in the entry of inflammatory leukocytes into lesions. This process, if left unchecked, impedes resolution and enables disease progress to endothelial dysfunction, vascular smooth muscle proliferation and associated clinical sequelae 177 . Reducing plasma low-density lipoprotein cholesterol levels using rosuvastatin or atorvastatin can promote regression of atherosclerotic lesions in humans 178 . In other words, removing the inciting stimulus is sufficient to help resolve this multifactorial chronic inflammatory disease. However, this statin-mediated effect is either obscured or negated in individuals with type 1 or type 2 diabetes. In murine models, hyperglycaemia is associated with increased numbers of circulating monocytes -especially inflammatory LY6C + monocytes 179 -and polymorphonuclear cells (PMNs) 180 , which leads to their increased, proportional entry into plaques and consequent accelerated lesion progression. This seems to be replicated clinically: compared with individuals who have atherosclerosis alone, individuals with atherosclerosis and diabetes show impaired regression in response to cholesterolreducing therapies 181 , emphasizing the challenge of attempting to pharmacologically resolve clinical disease.
Perhaps the optimal pragmatic course for demonstrating the potential of pro-resolution strategies would be a combination of studies on healthy humans and rodents. To this end, several human models to explore innate immunity and inflammation are now available. Skin represents a reproducible and clinically-relevant window into the human immune system, and there are several methods to elicit local inflammation -including exposure to cantharidin [182] [183] [184] [185] , which causes acantholysis. This sterile tissue-injury model is driven by damage-associated molecular pattern molecules (DAMPs) such as purines, S100 proteins and nucleic acids. The elicited inflammatory response is characterized by rapid PMN infiltration followed by recruitment of macrophages and a smaller proportion of lymphocytes. Although responsive to many traditional anti-inflammatory drugs, the utility of this model is limited in temporal duration (<72 hours) by blister stability. Other models include intradermal injection of endotoxin 186 or lung inhalation of endotoxin 187 . Both of these trigger a robust innate immune response that spontaneously resolves and may better facilitate exploration of post-resolution processes, offering a more 'physiological' system. Akbar and colleagues have additionally characterized the adaptive immune responses to recall antigens -including tuberculin purified protein, which was administered by intradermal injection and subsequent suction blister -as a means of understanding immunosenescence in aged human volunteers 188, 189 . Demonstration of the similarities of the fundamental biological processes that underlie resolution in these human models with those observed in animal studies to date will hopefully provide reassurance of their validity. Further development and appropriate selection of human inflammatory models, along with acquisition of dedicated clinical samples, will, however, be crucial in translating current theory to future therapy.
H 2 Sreleasing NSAID ATB346 (which is in Phase I for osteoarthritis) accelerates gastrointestinal wound repair (in stark contrast to its parental compound, naproxen, which causes gastrointestinal lesions) 149 . Such agents clearly demonstrate the potential of the incipient class of proresolving therapies.
Future strategies to target resolution Many advances have been made in understanding reso lution and its constituent processes; now, we must learn how to control these processes with convincing efficacy. For example, a range of factors have a role in inflam matory resolution, including lipids (such as lipoxins, resolvins, protectins, maresins and PGD 2 or cyclopen tenone prostaglandins), proteins (such as annexin A1 and secretory leukocyte protease inhibitor), proteins (such as annexin, melanocortin and chemerin derived peptides), gaseous mediators (such as H 2 S and carbon monoxide (CO)), purines (such as adenosine) as well as the vagal nerve release of acetylcholine into the affected tissue. Nevertheless, the question of where, when and how to therapeutically employ or manipulate these moieties still remains.
Existing antiinflammatories also possess pro resolution properties: lowdose aspirin triggers the production of epimeric forms of lipoxins (15epi lipoxin A 4 and 15epilipoxin B 4 ) and glucocorticoids enhance efferocytosis. However, such drugs have unwanted side effects. Nevertheless, it is now clear that a better understanding of their pharmacological mech anisms of proresolving action may be able to obviate these. For example, recent insights into melanocortin receptors have reinvigorated interest in the use of adreno corticotophic hormone (ACTH) as a drug. ACTH not only induces cortisol production but also exerts anti inflammatory actions by: targeting melanocortin recep tors present on immune cells; inhibiting granulocyte trafficking; suppressing cytokine synthesis; and driv ing macrophages towards an M2like phenotype 150 . These findings suggest that new ACTHlike melano cortin receptortargeting drugs devoid of steroidogenic actions could possess potent proresolution effects 150 . Equally, forms of lipoxins that are endogenously pro duced following exposure to aspirin (known as aspirin triggered lipoxins (ATLs)), or longlived mimetics of these, may afford similar benefits to aspirin without the gastrointestinal and haemorrhagic sequelae.
Theoretically, proresolution therapies may be supe rior to standard antiinflammatories, in that, as well as suppressing the first four cardinal signs of inflamma tion, they may also affect tissue healing and function. Early evidence comes from murine studies of inflam mationinduced bone loss. Proinflammatory cytokines such as TNF and IL1 promote pathologic osteoclast resorption of bone and suppress the ability of osteo blasts to counteract bone erosion; however, during the resolution phase of the mouse K/BxN seruminduced inflammatory arthritis model, bone resorption ceased and appositional osteoblastmediated bone formation was induced 151 . Remarkably, this resulted in repair of eroded bone -probably as a result of downregula tion of the WNT antagonists secreted frizzledrelated protein 1 (sFRP1) and sFRP2, and concomitant induc tion of the anabolic and promatrix mineralization factors WNT10.
Finally, and potentially most importantly, the trans lation of proresolution strategies to humans is under way. The findings that membrane anti inflammatory GPCRs including chemokinelike receptor 1 (CMKLR1; also known as ChemR23), GPR32 and FPR2 transduce the proresolving effects of chemerin peptides RvE1 and RvD1 (and that RvD2 exerts its effects through GPR18 (REF. 152)) not only are novel and exciting developments in receptor biology, but also may represent an important opportunity for proresolution drug discovery. A better understanding of these recep tors, especially in chronic inflammatory settings, could guide novel drug discovery programmes aimed at using the fundamental actions of these effectors of resolution. This process has already started with a stable isopropyl ester analogue of RvE1, RX10045 (Auven Therapeutics/Resolvyx Pharmaceuticals), which is being tested for its ability to resolve dry eye inflammation 153 .
Box 4 | Murine and zebrafish models
In mice, the effects of putative anti-inflammatory and pro-resolution drugs can be traced over time using the 'industrial standard' oxazolone ear-swelling (type IV hypersensitivity) and carrageenan-induced paw-swelling models. These models also enable each animal to serve as its own control, meaning smaller numbers of mice need be used -particularly useful when using precious transgenic mice or in quick proof-of-principle investigations. Whereas the readouts of these models centre on oedema formation, they may be complemented with peritonitis and pleuritis models that use sterile stimuli such as zymosan, which enable greater insight into leukocyte dynamics and access to inflammatory exudates that contain soluble mediators.
It is important to bear in mind idiosyncratic features of individual models of different diseases in different species, genetic manipulations, and organs or tissues. For example, it is ill-advised to use transgenic mice with the air-pouch model, owing to the possibility that the intra-pouch fibro-vascular lining that is needed to enumerate the inflammatory response may be dependent on expression of the gene of interest during development, although this concern can be mitigated by using conditional knockouts.
Originally, termination of polymorphonuclear cell (PMN) influx, efferocytosis and cytokine clearance were considered adequate metrics of resolution; however, these quickly became insufficient 17, 190 . Quantitative indices such as Ψ max (the maximal number of PMNs present during the inflammatory response), T max (the time at which Ψ max occurs) and the resolution interval (R i ) from T max to T 50 (when PMN numbers reach half Ψ max ) 126 became useful when quantifying the effects of pharmacological intervention or genetic manipulation on resolution. In turn, a new, more robust set of criteria will probably be required to assess the changes in the ability of resolution processes to bridge the gap between acute inflammation and adaptive immunity.
Zebrafish can also be used in inexpensive high-throughput screening of pro-resolution drugs. For example, tail fins can be surgically transected to cause a reproducible and robust inflammatory response that can be assessed by PMN counts or through fluorescence imaging of PMNs over time. In one study, injured zebrafish larvae with green fluorescent protein (GFP)-labelled PMNs were exposed to compounds from 4 hours post-injury (a time point when high numbers of PMNs have been recruited to the wound site) to 12 hours post-injury (when inflammation resolution was only partially complete in controls) 191 . Tanshinone IIA, which is derived from a Chinese medicinal herb, potently induced inflammation resolution by inducing PMN apoptosis and promoting reverse migration of PMNs. Tanshinone IIA also blocked pro-inflammatory signals in the zebrafish, and its effects were conserved in human PMNs, supporting the translational potential of this drug and this screening strategy.
